Active Ingredient History
Darbepoetin alfa (INN) is a re-engineered form of erythropoietin containing 5 amino acid changes resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta. It stimulates erythropoiesis by the same mechanism as rHuEpo and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Darbepoetin is marketed by Amgen under the trade name Aranesp. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Febrile Encephalopathy (Phase 2)
Acute Kidney Injury (Phase 2/Phase 3)
Androgens (Phase 2)
Anemia ()
Anemia, Iron-Deficiency (Phase 2)
Blood Pressure (Phase 2)
Brain Injuries, Traumatic (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Cardiomyopathies (Phase 4)
Cardiovascular Diseases (Phase 3)
Cognition Disorders (Phase 3)
Colorectal Neoplasms (Phase 4)
Diabetes Complications (Phase 2)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 2 (Phase 1)
Dialysis (Phase 4)
Drugs, Generic (Phase 4)
Dysgerminoma (Phase 2)
Erythroblastosis, Fetal (Phase 2/Phase 3)
Genital Neoplasms, Female (Phase 2)
Growth and Development (Phase 3)
Healthy Volunteers (Phase 1)
Heart Failure (Phase 3)
Hematologic Neoplasms (Phase 2/Phase 3)
Hyperparathyroidism (Phase 4)
Hypertension (Phase 1)
Hypoxia-Ischemia, Brain (Phase 1/Phase 2)
Immunization (Phase 2/Phase 3)
Infant, Newborn (Phase 2)
Infant, Premature, Diseases (Phase 2)
Iron Deficiencies (Phase 2)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Kidney Transplantation (Phase 4)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Lung Neoplasms (Phase 3)
Lymphoma (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoproliferative Disorders (Phase 3)
Multiple Myeloma (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Myocardial Infarction (Phase 3)
Neonatology (Phase 3)
Neoplasms (Phase 4)
Neuroprotection (Phase 3)
Neutropenia (Phase 2)
Optic Atrophy (Phase 1/Phase 2)
Precancerous Conditions (Phase 3)
Prostatic Neoplasms (Phase 2/Phase 3)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Reticulocyte Count (Phase 1)
Small Cell Lung Carcinoma (Phase 3)
Spinal Cord Ischemia (Phase 2)
Stroke (Phase 2)
Uterine Cervical Neoplasms (Phase 2)
Ventricular Dysfunction (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
